<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01299103</url>
  </required_header>
  <id_info>
    <org_study_id>PEL-10-02</org_study_id>
    <nct_id>NCT01299103</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Single Therapy Versus Double and Triple Therapy of the Pellevé™ Wrinkle Treatment System for the Treatment of Moderate Facial Wrinkles</brief_title>
  <official_title>A Prospective, Randomized, Open-Label, 3-Arm Parallel Study Comparing the Safety and Efficacy of Single Therapy Versus Double and Triple Therapy Using the Surgitron® Dual RF™ S5 With the Pellevé™ Wrinkle Treatment Handpiece and Pellevé™ Treatment Gel for the Treatment of Moderate Facial Wrinkles in Fitzpatrick Skin Types I - IV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ellman International</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ellman International</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will enroll and treat a patients to assess improvement in the appearance of facial&#xD;
      wrinkles.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will enroll and treat a total of 44 subjects (23 in treatment Group A receiving a&#xD;
      single treatment and 21 in treatment Group B receiving two treatments) with moderate facial&#xD;
      wrinkles corresponding to a grade of 4-6 on the validated Fitzpatrick Wrinkle Assessment&#xD;
      Scale.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fitzpatrick Wrinkle Assessment</measure>
    <time_frame>change in Fitzpatrick Wrinkle Score between baseline and 90 days post treatment assessment.</time_frame>
    <description>Subject photos will be evaluated using the 9-point Fitzpatrick Wrinkle Assessment Scale at all follow up visits. An improvement is noted by a decrease in the numeric Fitzpatrick Wrinkle score. The Fitzpatrick Wrinkle Assessment ranges from 1-9. Wrinkle Score between baseline and 90 days post treatment assessment. Positive values indicates an increase in score, while negative values indicate a decrease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>90 days post treatment</time_frame>
    <description>The rate of adverse events occurring in treatment subjects will be assessed.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Appearance of Facial Wrinkles</condition>
  <arm_group>
    <arm_group_label>Single Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of facial wrinkle with one treatment only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Double Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of facial wrinkle with two treatments</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of facial wrinkle with three treatments</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pelleve Wrinkle Treatment System</intervention_name>
    <description>comparison of single vs. double and triple treatment with the Pelleve Wrinkle Treatment System</description>
    <arm_group_label>Double Treatment</arm_group_label>
    <arm_group_label>Single Treatment</arm_group_label>
    <arm_group_label>Triple treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Females 35-60 years of age with Fitzpatrick Skin Color Type I-IV.&#xD;
&#xD;
          -  Subjects with clinical evidence of facial wrinkles mild to moderate in severity as&#xD;
             specified by a grade 4-6 on the Fitzpatrick Wrinkle Assessment Scale.&#xD;
&#xD;
          -  Willingness and ability to comply with protocol requirements, including returning for&#xD;
             follow-up visits and abstaining from exclusionary procedures for the duration of the&#xD;
             study.&#xD;
&#xD;
          -  Willingness and ability to provide written photo consent and adherence to photography&#xD;
             procedures (i.e., removal of jewelry and makeup).&#xD;
&#xD;
          -  Willingness and ability to provide written informed consent prior to performance of&#xD;
             any study related procedure.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who are pregnant, nursing, planning to become pregnant, and/or not using a&#xD;
             reliable form of birth control.&#xD;
&#xD;
          -  Subjects who have had prior exposure to any hyaluronic acid, or any other filler,&#xD;
             injection for any purpose in the 12 months preceding study enrollment through the&#xD;
             duration of the study.&#xD;
&#xD;
          -  Subjects who have had prior exposure to any botulinum toxin for facial rhytids in the&#xD;
             6 months preceding study enrollment through the duration of the study.&#xD;
&#xD;
          -  Subjects who have had a prior cosmetic procedure to improve facial rhytids (i.e.,&#xD;
             rhytidectomy, periorbital or eyelid/eyebrow surgery, brow lift, CO2/erbium laser&#xD;
             resurfacing, Thermage/Thermacool radiofrequency treatment) within 12 months or who&#xD;
             have visible scars that may affect evaluation of response and/or quality of&#xD;
             photography.&#xD;
&#xD;
          -  Ablative skin resurfacing on the glabellar area within the previous 6 months or during&#xD;
             the study.&#xD;
&#xD;
          -  Retinoid, microdermabrasion, or prescription level glycolic acid treatments within 3&#xD;
             months prior to study participation or during the study.&#xD;
&#xD;
          -  Active cut, wound, or infection on the skin.&#xD;
&#xD;
          -  Oral Isotretinon within the past 12 months.&#xD;
&#xD;
          -  Active HSV-1.&#xD;
&#xD;
          -  History of keloids or hypertrophic scarring.&#xD;
&#xD;
          -  Existing or history of skin malignancy.&#xD;
&#xD;
          -  Any existing skin disease.&#xD;
&#xD;
          -  History of collagen or vascular disease.&#xD;
&#xD;
          -  Subjects who have implantable pacemaker, automatic implantable defibrillator/&#xD;
             cadioversor (AICD), or any other implantable electric device.&#xD;
&#xD;
          -  Subjects who have used, within 30 days, any medication that can cause dermal&#xD;
             hypersensitivity or affect skin characteristics.&#xD;
&#xD;
          -  History of autoimmune disease.&#xD;
&#xD;
          -  History of any disease that inhibits pain sensation.&#xD;
&#xD;
          -  History of Diabetes I or II.&#xD;
&#xD;
          -  Concurrent therapy that, in the investigator's opinion, would interfere with the&#xD;
             evaluation of the safety or efficacy of the study medication.&#xD;
&#xD;
          -  Subjects who anticipate the need for surgery or overnight hospitalization during the&#xD;
             study.&#xD;
&#xD;
          -  Subjects who, in the Investigator's opinion, have a history of poor cooperation,&#xD;
             non¬compliance with medical treatment or unreliability.&#xD;
&#xD;
          -  Enrollment in any active study involving the use of investigational devices or drugs.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven H. Dayan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>DeNova Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DeNova Research Institute</name>
      <address>
        <city>Chichago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>February 4, 2011</study_first_submitted>
  <study_first_submitted_qc>February 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2011</study_first_posted>
  <results_first_submitted>November 10, 2014</results_first_submitted>
  <results_first_submitted_qc>March 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 15, 2016</results_first_posted>
  <last_update_submitted>March 28, 2016</last_update_submitted>
  <last_update_submitted_qc>March 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>wrinkle</keyword>
  <keyword>rhytide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Facies</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Treatment</title>
          <description>Subjects receive one treatment</description>
        </group>
        <group group_id="P2">
          <title>Double Treatment</title>
          <description>Subjects receive two treatments</description>
        </group>
        <group group_id="P3">
          <title>Triple Treatment</title>
          <description>Subjects receive three treatments</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Treatment</title>
          <description>Pelleve Wrinkle Treatment System: comparison of single vs. double and triple treatment with the Pelleve Wrinkle Treatment System</description>
        </group>
        <group group_id="B2">
          <title>Double Treatment</title>
          <description>Pelleve Wrinkle Treatment System: comparison of single vs. double and triple treatment with the Pelleve Wrinkle Treatment System</description>
        </group>
        <group group_id="B3">
          <title>Triple Treatment</title>
          <description>Pelleve Wrinkle Treatment System: comparison of single vs. double and triple treatment with the Pelleve Wrinkle Treatment System</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="40"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" spread="7.2"/>
                    <measurement group_id="B2" value="52" spread="6.5"/>
                    <measurement group_id="B3" value="53" spread="5.2"/>
                    <measurement group_id="B4" value="52" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fitzpatrick Wrinkle Assessment</title>
        <description>Subject photos will be evaluated using the 9-point Fitzpatrick Wrinkle Assessment Scale at all follow up visits. An improvement is noted by a decrease in the numeric Fitzpatrick Wrinkle score. The Fitzpatrick Wrinkle Assessment ranges from 1-9. Wrinkle Score between baseline and 90 days post treatment assessment. Positive values indicates an increase in score, while negative values indicate a decrease</description>
        <time_frame>change in Fitzpatrick Wrinkle Score between baseline and 90 days post treatment assessment.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Treatment</title>
            <description>Subjects receive one treatment</description>
          </group>
          <group group_id="O2">
            <title>Double Treatment</title>
            <description>Subjects receive two treatments</description>
          </group>
          <group group_id="O3">
            <title>Triple Treatment</title>
            <description>Subjects receive three treatments</description>
          </group>
        </group_list>
        <measure>
          <title>Fitzpatrick Wrinkle Assessment</title>
          <description>Subject photos will be evaluated using the 9-point Fitzpatrick Wrinkle Assessment Scale at all follow up visits. An improvement is noted by a decrease in the numeric Fitzpatrick Wrinkle score. The Fitzpatrick Wrinkle Assessment ranges from 1-9. Wrinkle Score between baseline and 90 days post treatment assessment. Positive values indicates an increase in score, while negative values indicate a decrease</description>
          <units>units on a scale, change in Fitzpatrick</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.98"/>
                    <measurement group_id="O2" value="1.5" spread="1.9"/>
                    <measurement group_id="O3" value="1.1" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events</title>
        <description>The rate of adverse events occurring in treatment subjects will be assessed.</description>
        <time_frame>90 days post treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Treatment</title>
            <description>Subjects receive one treatment</description>
          </group>
          <group group_id="O2">
            <title>Double Treatment</title>
            <description>Subjects receive two treatments</description>
          </group>
          <group group_id="O3">
            <title>Triple Treatment</title>
            <description>Subjects receive three treatments</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events</title>
          <description>The rate of adverse events occurring in treatment subjects will be assessed.</description>
          <units>number of adverse events reported</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Single Treatment</title>
          <description>Subjects receive one treatment</description>
        </group>
        <group group_id="E2">
          <title>Double Treatment</title>
          <description>Subjects receive two treatments</description>
        </group>
        <group group_id="E3">
          <title>Triple Treatment</title>
          <description>Subjects receive three treatments</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Steven Dayan</name_or_title>
      <organization>Chicago Center for Facial Plastic Surgery</organization>
      <phone>(312) 335-2070</phone>
      <email>sdayan@drdayan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

